Weight loss drugs, such as those containing GLP-1 agonists like Wegovy and Mounjaro, have emerged as effective tools for ...

CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...

Ozempic and Wegovy are increasingly available in Australia and worldwide to treat type 2 diabetes and obesity. The dramatic ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...

The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...

AI in drug development is a vague term that might mean many things, and today, Owkin is announcing it has enrolled the first patient in a phase 1 study of OKN4395, its “AI-optimized” candidate for ...

Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a serious complication.

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. The approval supports evidence ...

Salk scientists identify protein BCL6 as a key regulator of muscle maintenance in mice; BCL6-enhancing therapies may prevent ...